Affimed NV (LTS:0HL9)
$ 6.1 -0.37 (-5.72%) Market Cap: 93.50 Mil Enterprise Value: 35.19 Mil PE Ratio: 0 PB Ratio: 1.46 GF Score: 50/100

Affimed NV Conference Call Transcript

Dec 11, 2023 / 09:30PM GMT
Release Date Price: $3.79 (+1.47%)
Operator

Thank you for standing by, and welcome to Affimed's clinical data update on Acimtamig AFM13 and AFM24 conference call. (Operator Instructions) Please be advised, today's call is being recorded. I will now turn the call over to your host, Mr. Alex Fudukidis, Director, Investor Relations. Please go ahead.

Alex Fudukidis
Affimed N.V. - Head of IR & Director of IR

Thank you, Valerie.

Good day, everyone, and welcome to Affimed's investor event during the 65th annual American Society of Hematology Annual Meeting and Exposition in San Diego. As a reminder, today's webcast is being recorded and the recording will be available through our website later today.

Before we begin, I'd like to remind everyone that we issued two press releases earlier today, one about our investigator-sponsored combination trial of Acimtamig AFM13 with cord blood-derived natural killer cells data, which was presented earlier today at the ASH conference and a press release on the progress we're making with AFM24 our solid tumor clinical assets.

Before propel

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot